Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 12/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 6/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.78 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15721372 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL12830850 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL14107503 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL14153815 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL11778970 | 0.94 | OPRM1 (0.89) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13250907 | 0.91 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3476307 | 0.91 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL16922125 | 0.91 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3475284 | 0.91 | OPRD1 (0.85) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL24579 | 0.91 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405301-B2 | Chemical methods | GLAXOWELLCOME AUSTRALIA LTD. (AU) | 2008-07-29 | — | — | US | claimed |
| EP-1560833-A2 | PREPARATION OF CODEINE FROM MORPHINE | Mallinckrodt International Corporation (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004037826-A2 | PREPARATION OF CODEINE FROM MORPHINE | MALLINCKRODT INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077863-A1 | Chemical methods | GLAXO WELLCOME AUSTRALIA LTD. (AU) | 2004-04-22 | — | — | US | claimed |
| US-6579985-B1 | Preparation of codeine from morphine | MALLINCKRODT INC. | 2003-06-17 | — | — | US | claimed |
| WO-2002016367-A1 | CHEMICAL METHODS | GLAXO WELLCOME AUSTRALIA LTD (AU) | 2002-02-28 | — | — | WO | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536138-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20010005754-A1 | Method for preparing oxycodone | CHIU FANG-TING (US) | 2001-06-28 | — | — | US | disclosed |
| WO-2001029048-A2 | METHOD FOR PREPARING OXYCODONE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029047-A2 | METHOD FOR PREPARING OXYCODONE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| US-6177567-B1 | FORMATION OF AN DIENOLSILYL ETHER CONGENER OF CODEINONE; OXIDATION OF THE DIENOLSILYL ETHER CONGENER AND HYDROGENATION OF THE RESULTING 14-HYDROXYCODEINONE PRODUCT. | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2001-01-23 | — | — | US | disclosed |
| US-6090943-A | Preparation of opiates, intermediates and uses of salts | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2000-07-18 | — | — | US | disclosed |
| EP-0889045-A1 | Process for the production of thebaine and analogues thereof, as well as intermediate products therefor | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1999-01-07 | — | — | EP | disclosed |
| US-4045440-A | ETHERIFICATION WITH METHYL IODIDE, OXIDATION WITH MANGANESE DIOXIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRM1 4810/4885OPRK1 2862/4885OPRD1 4518/4885 |
| US-20010005754-A1 | Method for preparing oxycodone | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRK1 1/4885OPRD1 3/4885 |
| US-20040077863-A1 | Chemical methods | TET2, TET1, DNMT1 | OPRM1 273/4885OPRK1 1562/4885OPRD1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.